166 related articles for article (PubMed ID: 12121962)
1. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.
Delmas G; Park S; Chen ZW; Tan F; Kashiwazaki R; Zarif L; Perlin DS
Antimicrob Agents Chemother; 2002 Aug; 46(8):2704-7. PubMed ID: 12121962
[TBL] [Abstract][Full Text] [Related]
2. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.
Segarra I; Movshin DA; Zarif L
J Pharm Sci; 2002 Aug; 91(8):1827-37. PubMed ID: 12115810
[TBL] [Abstract][Full Text] [Related]
4. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
Denning DW; Warn P
Antimicrob Agents Chemother; 1999 Nov; 43(11):2592-9. PubMed ID: 10543734
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.
Santangelo R; Paderu P; Delmas G; Chen ZW; Mannino R; Zarif L; Perlin DS
Antimicrob Agents Chemother; 2000 Sep; 44(9):2356-60. PubMed ID: 10952579
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D and experimental invasive aspergillosis.
Sirivoranankul C; Martinez M; Chen V; Clemons KV; Stevens DA
Med Mycol; 2014 Nov; 52(8):847-52. PubMed ID: 25231772
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.
Saxena S; Ghosh PC
Pharm Res; 2000 Oct; 17(10):1236-42. PubMed ID: 11145229
[TBL] [Abstract][Full Text] [Related]
10. [Cerebral aspergillosis in an HIV-infected patient: unsuccessful outcome despite combined antifungal therapy. ].
Gasch O; Fernández N; Ayats J; Santin M
Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):193-4. PubMed ID: 19306722
[No Abstract] [Full Text] [Related]
11. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.
Patterson TF; Miniter P; Dijkstra J; Szoka FC; Ryan JL; Andriole VT
J Infect Dis; 1989 Apr; 159(4):717-24. PubMed ID: 2926162
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis.
Saxena S; Khan JA; Ghosh PC
J Antimicrob Chemother; 1998 Nov; 42(5):635-42. PubMed ID: 9848448
[TBL] [Abstract][Full Text] [Related]
15. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Allendoerfer R; Loebenberg D; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1995 Jun; 39(6):1345-8. PubMed ID: 7574528
[TBL] [Abstract][Full Text] [Related]
17. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
18. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B.
Chang T; Olson JA; Proffitt RT; Adler-Moore JP
Med Mycol; 2010 Mar; 48(2):430-5. PubMed ID: 20141377
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
Souza LC; Campa A
J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
[TBL] [Abstract][Full Text] [Related]
20. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
